Sector News

Horizon hikes Depomed offer to $2B in bid for ‘friendly’ deal talks

July 21, 2015
Life sciences
Don’t get Horizon Pharma wrong. It intends to pursue Depomed as an M&A target whether the California company likes it or not. But it would prefer for Depomed to like it–and in an effort to spur a “friendly, negotiated transaction,” it’s raising its bid.
 
Tuesday, the Irish pharma put forth a $33 per share proposal–up from its previous $29.25-per-share offer. The new bid represents a 60% premium to Depomed’s share price the day before Horizon took its intentions public, or about $1.97 billion. But that price is contingent on Depomed “rapidly entering into good faith discussions regarding a transaction,” Horizon CEO Timothy Walbert wrote in a letter to his target’s board.
 
On that front, Walbert said his company remains “surprised and disappointed” that Depomed hasn’t yet come to the bargaining table. Based on talks Horizon has had with shareholders on both sides, “it is clear that they and the investment community strongly support a combination of our two businesses,” he said in a statement.
 
For its part, Depomed so far hasn’t shown any signs that it’s up for a buyout. Last week, it adopted a poison pill plan that would be triggered if any person or group picks up an ownership stake larger than 10%.
 
But Depomed’s reticence won’t stop Horizon from moving forward, Walbert stressed: “Horizon remains committed to an acquisition of Depomed and we are prepared to consider all paths necessary to complete the transaction,” he said.
 
By Carly Helfand
 

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.